May Vertex Update- VX661 adds further benefit to those on Kalydeco with G551D/F508del

I've just summarised the May 1 Vertex investor conference, includes info about Kalydeco, VX809 & VX661: http://sixtyfiverosesblog.wordpress....vertex-update/ Also, it was announced on May 1 that the trial adding VX661 to patients stable on Kalydeco (with G551D/F508del), showed further improvements in FEV1 (+4.6%) and sweat chloride (-7mmol/L). My blog post above has more info about this. In theory this means that people who are likely respond to Kalydeco (gating, residual function) who also have F508del, may see further benefits when a corrector is added.
Source: Cystic Fibrosis CFTR Modulation and Gene Therapy Forum - Category: Respiratory Medicine Authors: Tags: CFTR Modulation and Gene Therapy Talk Source Type: forums